Pfizer's migraine drug, Relpax, has been stuck at the FDA since late 1998, despite getting two separate letters from the FDA indicating approval was likely.
FORBES: Crisis in the Cabinet
The agency now frets over Relpax's effects on the heart.
应用推荐
模块上移
模块下移
不移动